Combining Heterogeneous Databases to Detect Adverse Drug Reaction

[1]  Graciela Gonzalez-Hernandez,et al.  Utilizing social media data for pharmacovigilance: A review , 2015, J. Biomed. Informatics.

[2]  Martijn J. Schuemie,et al.  Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection , 2015, International Journal of Clinical Pharmacy.

[3]  Hua Xu,et al.  Identifying Plausible Adverse Drug Reactions Using Knowledge Extracted from the Literature , 2014, AMIA.

[4]  Olivier Bodenreider,et al.  A time-indexed reference standard of adverse drug reactions , 2014, Scientific Data.

[5]  G Hripcsak,et al.  Similarity-Based Modeling Applied to Signal Detection in Pharmacovigilance , 2014, CPT: pharmacometrics & systems pharmacology.

[6]  Taha A. Kass-Hout,et al.  Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter , 2014, Drug Safety.

[7]  E. Horvitz,et al.  Toward Enhanced Pharmacovigilance Using Patient-Generated Data on the Internet , 2014, Clinical pharmacology and therapeutics.

[8]  David A. Moskowitz,et al.  The role of media and the Internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination. , 2014, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[9]  Ying Li,et al.  A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records , 2014, J. Am. Medical Informatics Assoc..

[10]  Noémie Elhadad,et al.  Natural Language Processing in Health Care and Biomedicine , 2014 .

[11]  Rong Xu,et al.  Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection , 2013, BMC Bioinformatics.

[12]  A. Belloni,et al.  HONEST CONFIDENCE REGIONS FOR A REGRESSION PARAMETER IN LOGISTIC REGRESSION WITH A LARGE NUMBER OF CONTROLS , 2013 .

[13]  M. Schuemie,et al.  Defining a Reference Set to Support Methodological Research in Drug Safety , 2013, Drug Safety.

[14]  Patrick B. Ryan,et al.  Alternative Outcome Definitions and Their Effect on the Performance of Methods for Observational Outcome Studies , 2013, Drug Safety.

[15]  D. Madigan,et al.  A Comparison of the Empirical Performance of Methods for a Risk Identification System , 2013, Drug Safety.

[16]  Carol Friedman,et al.  Natural language processing: State of the art and prospects for significant progress, a workshop sponsored by the National Library of Medicine , 2013, J. Biomed. Informatics.

[17]  William DuMouchel,et al.  Empirical bayes model to combine signals of adverse drug reactions , 2013, KDD.

[18]  N. Shah,et al.  Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.

[19]  N. Shah,et al.  Pharmacovigilance Using Clinical Notes , 2013, Clinical pharmacology and therapeutics.

[20]  Marius Fieschi,et al.  Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project , 2013, J. Am. Medical Informatics Assoc..

[21]  Carol Friedman,et al.  Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions , 2013, J. Am. Medical Informatics Assoc..

[22]  Ryen W. White,et al.  Web-scale pharmacovigilance: listening to signals from the crowd , 2013, J. Am. Medical Informatics Assoc..

[23]  Miriam Sturkenboom,et al.  Postmarketing Safety Surveillance , 2013, Drug Safety.

[24]  David Madigan,et al.  Disproportionality methods for pharmacovigilance in longitudinal observational databases , 2013, Statistical methods in medical research.

[25]  Y. Okuno,et al.  Data Mining of the Public Version of the FDA Adverse Event Reporting System , 2011, International journal of medical sciences.

[26]  Johan Hopstadius,et al.  Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.

[27]  D. Madigan,et al.  Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.

[28]  C. Friedman,et al.  Detection of Pharmacovigilance‐Related Adverse Events Using Electronic Health Records and Automated Methods , 2012, Clinical pharmacology and therapeutics.

[29]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[30]  P. Coloma.  Mining Electronic Healthcare Record Databases to Augment Drug Safety Surveillance , 2012 .

[31]  Sonja Brajovic,et al.  Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration , 2012, Pharmacoepidemiology and drug safety.

[32]  P Ryan,et al.  Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.

[33]  Hua Xu,et al.  Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..

[34]  Sebastian Schneeweiss,et al.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system , 2012, Clinical pharmacology and therapy.

[35]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[36]  Martijn J. Schuemie,et al.  A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection Using Electronic Healthcare Record Databases , 2012, Drug Safety.

[37]  Russ B. Altman,et al.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports , 2012, J. Am. Medical Informatics Assoc..

[38]  Carol Friedman,et al.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis , 2011, J. Am. Medical Informatics Assoc..

[39]  Azadeh Nikfarjam,et al.  Pattern mining for extraction of mentions of Adverse Drug Reactions from user comments. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[40]  Siddhartha R. Dalal,et al.  Using information mining of the medical literature to improve drug safety , 2011, J. Am. Medical Informatics Assoc..

[41]  Lucila Ohno-Machado,et al.  Natural language processing: an introduction , 2011, J. Am. Medical Informatics Assoc..

[42]  R. Altman,et al.  Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.

[43]  M Alan Brookhart,et al.  The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration , 2011, Pharmacoepidemiology and drug safety.

[44]  D. Classen,et al.  'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. , 2011, Health affairs.

[45]  Martijn J Schuemie,et al.  Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD , 2011, Pharmacoepidemiology and drug safety.

[46]  M. Schuemie,et al.  Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.

[47]  Shawn E. Simpson.  Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data , 2011 .

[48]  C. Friedman,et al.  A drug-adverse event extraction algorithm to support pharmacovigilance knowledge mining from PubMed citations. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[49]  Manfred Hauben,et al.  An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database , 2010, Drug safety.

[50]  Michael A. Labuzetta,et al.  Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting , 2010, Pharmacoepidemiology and drug safety.

[51]  Carol Friedman,et al.  Mining electronic health records for adverse drug effects using regression based methods , 2010, IHI.

[52]  J. Overhage,et al.  Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.

[53]  Prakash M. Nadkarni,et al.  Drug safety surveillance using de-identified EMR and claims data: issues and challenges , 2010, J. Am. Medical Informatics Assoc..

[54]  Sunghwan Sohn,et al.  Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications , 2010, J. Am. Medical Informatics Assoc..

[55]  David Madigan,et al.  Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database , 2010 .

[56]  Jian Yang,et al.  Towards Internet-Age Pharmacovigilance: Extracting Adverse Drug Reactions from User Posts in Health-Related Social Networks , 2010, BioNLP@ACL.

[57]  J. Rassen,et al.  Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.

[58]  A. Borobia,et al.  A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients , 2010, Clinical pharmacology and therapeutics.

[59]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[60]  A. Fourrier-Réglat,et al.  The EU-ADR project: preliminary results and perspective. , 2009, Studies in health technology and informatics.

[61]  R. Platt,et al.  The new Sentinel Network--improving the evidence of medical-product safety. , 2009, The New England journal of medicine.

[62]  A. Pariente,et al.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.

[63]  Uwe Siebert,et al.  Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retr , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[64]  Ling Liu,et al.  Encyclopedia of Database Systems , 2009, Encyclopedia of Database Systems.

[65]  Xiaoyan Wang,et al.  Characterizing environmental and phenotypic associations using information theory and electronic health records , 2009, BMC Bioinformatics.

[66]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[67]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[68]  Xiaoyan Wang,et al.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. , 2009, Journal of the American Medical Informatics Association : JAMIA.

[69]  Mark A. Musen,et al.  The Open Biomedical Annotator , 2009, Summit on translational bioinformatics.

[70]  Manfred Hauben,et al.  Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions , 2009, Drug safety.

[71]  David Madigan,et al.  An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database , 2009, Drug safety.

[72]  Elinor Miller,et al.  Relationship of ethnic origin, gender, and age to blood creatine kinase levels. , 2009, The American journal of medicine.

[73]  Jeffrey R Curtis,et al.  Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data: Coxib Safety as an Example , 2008, Medical care.

[74]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[75]  Jesse A Berlin,et al.  Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.

[76]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[77]  George Hripcsak,et al.  Automated acquisition of disease drug knowledge from biomedical and clinical documents: an initial study. , 2008, Journal of the American Medical Informatics Association : JAMIA.

[78]  John F. Hurdle,et al.  Extracting Information from Textual Documents in the Electronic Health Record: A Review of Recent Research , 2008, Yearbook of Medical Informatics.

[79]  George Hripcsak,et al.  A statistical methodology for analyzing co-occurrence data from a large sample , 2007, J. Biomed. Informatics.

[80]  Jianjun Li,et al.  Drug-induced acute pancreatitis: an evidence-based review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[81]  W. Hersh.  Adding value to the electronic health record through secondary use of data for quality assurance, research, and surveillance. , 2007, The American journal of managed care.

[82]  A. Breckenridge.  The Future of Drug Safety , 2007, Clinical pharmacology and therapeutics.

[83]  Charles Safran,et al.  Toward a national framework for the secondary use of health data: an American Medical Informatics Association White Paper. , 2007, Journal of the American Medical Informatics Association : JAMIA.

[84]  Ola Caster,et al.  Mining the WHO Drug Safety Database Using Lasso Logistic Regression , 2007 .

[85]  B. Psaty,et al.  Protecting the health of the public--Institute of Medicine recommendations on drug safety. , 2006, The New England journal of medicine.

[86]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[87]  Til Stürmer,et al.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. , 2006, Journal of clinical epidemiology.

[88]  Robert W. Makuch,et al.  Detecting Rare Adverse Events in Postmarketing Studies: Sample Size Considerations , 2006 .

[89]  Hinrich Schütze,et al.  Introduction to information retrieval , 2008 .

[90]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[91]  Wei Ma,et al.  RxNorm: prescription for electronic drug information exchange , 2005, IT Professional.

[92]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[93]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[94]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[95]  Charles X. Ling,et al.  Using AUC and accuracy in evaluating learning algorithms , 2005, IEEE Transactions on Knowledge and Data Engineering.

[96]  J. Tisdale,et al.  Drug-Induced Diseases: Prevention, Detection, and Management , 2005 .

[97]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[98]  George Hripcsak,et al.  Automated encoding of clinical documents based on natural language processing. , 2004, Journal of the American Medical Informatics Association : JAMIA.

[99]  Kenneth J Rothman,et al.  The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.

[100]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[101]  Lehana Thabane,et al.  Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.

[102]  Carol Friedman,et al.  Extracting Phenotypic Information from the Literature via Natural Language Processing , 2004, MedInfo.

[103]  Olivier Bodenreider,et al.  The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..

[104]  N. Jewell.  Statistics for Epidemiology , 2003 .

[105]  Syed Rizwanuddin Ahmad,et al.  Adverse drug event monitoring at the food and drug administration , 2003, Journal of general internal medicine.

[106]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[107]  Emma Heeley,et al.  Automated Signal Generation in Prescription-Event Monitoring , 2002, Drug safety.

[108]  Andrew Herxheimer,et al.  Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance , 2002 .

[109]  Wendy W. Chapman,et al.  A Simple Algorithm for Identifying Negated Findings and Diseases in Discharge Summaries , 2001, J. Biomed. Informatics.

[110]  M. Braun,et al.  Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. , 2001, Vaccine.

[111]  H. Morgenstern,et al.  Confounding in health research. , 2001, Annual review of public health.

[112]  Alan R. Aronson,et al.  Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program , 2001, AMIA.

[113]  M. Lindquist,et al.  A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database , 2000, Drug safety.

[114]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[115]  A. Wall,et al.  Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .

[116]  D W Bates,et al.  Incidence and preventability of adverse drug events in nursing homes. , 2000, The American journal of medicine.

[117]  D. Coulter.  The New Zealand intensive medicines monitoring programme in pro‐active safety surveillance , 2000, Pharmacoepidemiology and drug safety.

[118]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[119]  G A Colditz,et al.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. , 1999, JAMA.

[120]  T. Brennan,et al.  Costs of medical injuries in Utah and Colorado. , 1999, Inquiry : a journal of medical care organization, provision and financing.

[121]  W. Amery.  Why there is a need for pharmacovigilance , 1999, Pharmacoepidemiology and drug safety.

[122]  R. Raschke,et al.  A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. , 1998, JAMA.

[123]  B. Bégaud,et al.  Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system , 1998, European Journal of Clinical Pharmacology.

[124]  S. Olsson,et al.  The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts , 1998, Drug safety.

[125]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[126]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[127]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[128]  N. Black.  Why we need observational studies to evaluate the effectiveness of health care , 1996, BMJ.

[129]  R. O’Neill,et al.  Does Research Synthesis Have a Place in Drug Regulatory Policy? Synopsis of Issues: Assessment of Safety and Postmarketing Surveillance , 1996 .

[130]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[131]  J. A. Johnson,et al.  Drug-Related Morbidity and Mortality: A Cost-of-Illness Model , 1995 .

[132]  N. Laird,et al.  Incidence of adverse drug events and potential adverse drug events , 1995 .

[133]  F. Speizer,et al.  Silicone breast implants and the risk of connective-tissue diseases and symptoms. , 1995, The New England journal of medicine.

[134]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[135]  D J Graham,et al.  Temafloxacin syndrome: review of 95 cases. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[136]  D A Kessler,et al.  Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. , 1993, General hospital psychiatry.

[137]  B. Rosner,et al.  A quantitative assessment of oral contraceptive use and risk of ovarian cancer , 1992, Obstetrics and gynecology.

[138]  G. Upton.  Fisher's Exact Test , 1992 .

[139]  R. Crosby,et al.  Observations on increased CPK levels in "asymptomatic" cocaine abusers. , 1992, Journal of addictive diseases.

[140]  W. Inman,et al.  Prescription-event monitoring: methodology and recent progress. , 1990, Journal of clinical epidemiology.

[141]  R. Sanson-Fisher,et al.  Patients as a direct source of information on adverse drug reactions. , 1988, BMJ.

[142]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[143]  D. Coulter,et al.  Cough associated with captopril and enalapril. , 1987, British medical journal.

[144]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[145]  C. Gouriéroux,et al.  Likelihood Ratio Test, Wald Test, and Kuhn-Tucker Test in Linear Models with Inequality Constraints on the Regression Parameters , 1982 .

[146]  H. Popper,et al.  Etiology of acute pancreatitis , 1942 .